American Shared Hospital Services (AMS)
AMEXHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
$1.43-2.05%
Close 2026-09-04 · 1-day change
AMEXHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
QuarterlyIQ Insights · AMS
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue increasing patient procedure volumes and expand the installed base of advanced radiation therapy technologies including Gamma Knife and Proton Beam Radiation Therapy.
Stated as a priority in 3 of last 3 quarters. Revenue grew from $7.1M in 2025-Q2 to $8.4M in 2026-Q2 (+19%), driven by 40% growth in Direct Patient Services revenue to $4.9M and 22% growth in Proton Beam Radiation Therapy revenue to $2.3M. Management is delivering on growing procedure volumes and expanding clinical capacity with improving utilization and geographic footprint.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Our priorities remain clear: continue growing procedure volumes, expand our installed base of advanced radiation therapy technologies.”
“We are encouraged by continued momentum in our direct patient care services segment and improved utilization across our treatment centers.”
“We remain focused on strengthening our partnerships, expanding clinical capacity, and driving long-term growth.”
Focus on strengthening the balance sheet, managing capital prudently, and executing financing initiatives to support growth and liquidity.
Stated as a priority in 3 of last 3 quarters. Cash and equivalents rose from $3.7M at 2025-Q4 to $6.8M at 2026-Q2, while current portion of long-term debt decreased from $17.3M to $16.2M. Management has executed a Third Amendment to its Credit Agreement and secured subordinated financing, delivering progress on strengthening financial position and capital structure.
“We continue to address our capital structure, strengthening our financial position and executing disciplined capital allocation.”
“We are actively focused on enhancing our capital structure to support the next phase of growth.”
“We remain focused on strengthening our balance sheet and creating value through disciplined capital allocation.”
Drive positive operating cash flow and improve operating efficiencies across treatment centers to support sustainable growth.
Stated as a priority in 3 of last 3 quarters. Operating cash flow improved from negative $0.7M in 2025-Q4 to positive $2.1M in 2026-Q1 and 2026-Q2, totaling $4.4M in first half 2026. Management is delivering improved operating efficiencies and cash generation supporting sustainable growth.
“Cash provided by operating activities totaled $4.4 million during the first six months of 2026.”
“Operating cash flow reached $2.1 million in the first quarter of 2026.”
“We remain focused on improving operating efficiencies and disciplined working capital management.”
Grow international procedure volumes and upgrade technology platforms such as the Esprit system to improve patient throughput and operating performance.
Stated as a priority in 2 of last 3 quarters. International Gamma Knife revenue grew 56% to $2.7M in first half 2026, driven by increased treatment volumes and Esprit system upgrades in Peru improving throughput. Management is delivering growth and operational improvements in international operations.
“International Gamma Knife revenue increased 56% during the first six months of 2026 as treatment volumes increased at international centers.”
“International procedure volumes increased significantly especially at the Peru facility following Esprit system upgrade.”
Focus on strengthening partnerships and expanding clinical capacity to drive long-term growth.
Over the trailing year it converted 0.39x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity, the US dollar (low R² over the window).
15 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.